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We studied familial risks in invasive and in situ
cutaneous melanoma by comparing the occurrence of
melanoma, or discordant cancer, between parents and
o¡spring, and between siblings, based on the Swedish
Family Cancer Database of over 10 million individuals.
O¡spring were 0^66 y of age. Cancers were obtained
from the Swedish Cancer Registry from 1961 to 1998.
The study was based on 24,818 invasive and 5510 in situ
cases of melanoma. Standardized incidence ratios were
calculated for familial risk. The standardized incidence
ratios for o¡spring was 2.40 (95% con¢dence intervals:
2.10^2.72) when only the parent had melanoma and it
was 2.98 (95% con¢dence intervals: 2.54^3.47) when only
a sibling was a¡ected; when both a parent and a sibling
were a¡ected the standardized incidence ratios was 8.92
(95% con¢dence intervals: 4.25^15.31). The respective
population attributable risks were 1.38, 1.20, and 0.10%.
The familial risk showed a clear age dependence and
somewhat higher risk in in situ melanoma than in the
invasive counterpart. The highest standardized inci-
dence ratio of 61.78 (5.82^227.19) was noted for o¡spring
whose parent had multiple melanomas. Super¢cially
spreading melanoma showed the highest familial risk
both among invasive and in situ tumors. Melanoma as-
sociated with breast, nervous system, and skin cancers,
and in situ melanoma possibly also with connective tis-
sue and thyroid tumors and multiple myeloma. Key
words: heredity/in situ melanoma/invasive melanoma/parent^
o¡spring risks/sibling risks. J Invest Dermatol 120:217 ^223,
2003
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unburn and overexposure to sun are the main environ-
mental risk factors of melanoma (English et al, 1997).
Familial risks in population-based studies have been
over 2.00 between ¢rst-degree relatives (Goldgar et al,
1994; Hemminki et al, 2001c). Inherited traits such as
density of nevi, skin type, and pigmentation, and color of hair
and eyes appear to explain a part of the familial risk by modulat-
ing the response to solar ultraviolet (UV) radiation or by other
mechanisms (English et al, 1997; Ang et al, 1998; Greene, 1998;
Zhu et al, 1999; Landi et al, 2001;Wachsmuth et al, 2001; Landi et
al, 2002). Associations with low-penetrance genes have been
sought in case-control studies of polymorphic candidate genes,
such as melanocortin-1 receptor, and many DNA repair genes
(Berwick and Vineis, 2000; Rees, 2000; Kennedy et al, 2001;
Scha¡er and Bolognia, 2001). Direct measurements of DNA re-
pair rates for UVdamage, however, have shown no di¡erence be-
tween melanoma patients and controls (Xu et al, 2000; Zhao et al,
2002). Several segregation analyses of melanoma have been car-
ried out with contradictory results. Evidence has been found
on genetic heterogeneity and complex patterns of inheritance
(Aitken et al, 1998).
Susceptibility to melanoma, particularly in families with
many a¡ected individuals is linked to mutations in the cell cycle
regulator CDKN2A (p16) gene, and less frequently to the CDK4
gene (Fearon, 1997; Harland et al, 1997; Aitken et al, 1999; Greene,
1999; Zhu et al, 1999). Mutations are rare in kindreds with a
fewer number of a¡ected individuals, however, e.g., only 7.8%
of the Swedish melanoma and dysplastic nevus syndrome
families show CDKN2A mutations; in many of these families
only two individuals were a¡ected (Platz et al, 1997); the
percentage has been 20% in the tested families from di¡erent
countries (Bishop et al, 2002). The CDKN2A gene also harbors
polymorphisms, which may modify risk for and survival in
melanoma (Kumar et al, 2001; Staume et al, 2002). Evidence has
been provided on the interactions of the CDKN2A and melanocor-
tin-1 receptor (van der Velden et al, 2001). Even if fragments of
the genetic basis of melanoma are understood, however, their
contribution to the total burden of familial melanoma remains
unknown.
The largest dataset ever used for family studies was utilized,
i.e., the Swedish Family Cancer Database with 1 million medi-
cally veri¢ed tumors and over 10 million individuals organized
in 3 million families.We analyzed familial risks in invasive and
in situ cutaneous melanoma by using parental and sibling pro-
bands and by considering multiple melanomas in the same indi-
vidual. Familial risks by histogenetic types were also determined.
Association of melanoma with other neoplasms in families was
determined. We also calculated population attributable fractions
(PAFS) for familial melanoma depending on the proband status.
PAF is an indicator of the population impact of a disease, i.e., the
proportion of melanoma that would disappear if the familial dis-
ease could be prevented (dos Santos Silva, 1999). These data
should provide guidance for clinical counseling and promote the
mechanistic understanding on melanoma.
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SUBJECTS AND METHODS
The Swedish Family Cancer Database, updated in 2000, includes persons
born in Sweden after 1931with their biologic parents, totaling over 10.2 mil-
lion individuals and organized in 3.2 million families (Hemminki andVaitti-
nen, 1998b; Hemminki et al, 1998). Cancers, including in situ tumors, were
retrieved from the nation-wide Swedish Cancer Registry from years 1961 to
1998. The completeness of cancer registration in the 1970s has been estimated
to be over 95%, and is now considered to be close to 100%. The percentage
of cytologically or histologically veri¢ed cases of melanoma has been 100%
in recent years (Center for Epidemiology, 2000).
A four-digit diagnostic code according to the seventh revision of the
ICD-7 has been used since 1958, together with a code for histologic type
(WHO/HS/CANC/24.1 Histology Code). From year 1993 onwards ICD-
O-2/ICD with histopathologic data according to the Systematized No-
menclature of Medicine (SNOMED, http://snomed.org) was used; we re-
fer to this classi¢cation as ‘‘histopathology’’or ‘‘histogenetic type’’. Only the
¢rst invasive or in situ melanoma was considered, if not stated otherwise.
All noti¢ed cases of melanoma in the Swedish Cancer Registry have been
histologically veri¢ed in the hospital of diagnosis. In a recent study an ex-
perienced pathologist review noti¢ed 5289 cases of invasive and in situmel-
anoma and agreed in 98.4% of the cases (Mansson-Brahme et al, 2002). The
results were not given separately for invasive and in situ melanoma, how-
ever, and we have no further data on the distinction of, for example, lenti-
go maligna melanoma and lentigo maligna in situ. Lentigo maligna
melanomawas rare, however, and it was not discussed in this paper because
there were no familial cases. The following ICD-7 codes were pooled:
‘‘oral’’ cancer codes 161 (larynx) and 140^148 (lip, mouth, pharynx), except
for code 142 (salivary glands) and ‘‘leukemia’’ codes 204^207 (leukemias),
208 (polycythemia vera), and 209 (myelo¢brosis). Rectal cancer, ICD-7
code 154 was separated for anus (squamous cell carcinoma, 154.1) and mu-
cosal rectum (154.0). Among the skin cancers, only squamous cell carcino-
ma is registered at the Cancer Registry.
Standardized incidence ratios (SIR) were used to measure the cancer
risks for o¡spring according to occurrence of cancers in their family (par-
ents or siblings were probands). SIR were calculated as the ratio of ob-
served (O) to expected (E) number of cases. The expected numbers of
cancers were obtained by assuming that these persons experienced the same
cancer incidence as prevailed in the corresponding general population in
the Database. O¡spring were diagnosed for their ¢rst primary cancer at
ages 0^66 y, whereas the age of parents at their diagnosis was not limited.
Tumor site, sex, 5 y age, period (10 y bands), socio-economic status (six
groups), and residential area (two groups) speci¢c standard incidence rates
were applied to the appropriate person-years at risk (Esteve et al, 1994). Per-
son-years at risk were accumulated for each o¡spring beginning with the
date of birth or January 1, 1961 and ending with the date of diagnosis of a
¢rst primary cancer, date of death, date of emigration, or December 31,
1998. Con¢dence intervals (95% CI) were calculated assuming that the
numbers of cancer cases among o¡spring follow a Poisson distribution (Es-
teve et al, 1994). Sibling risks were calculated using the cohort method as
described (Hemminki et al, 2001d). In the cohort method one de¢nes a co-
hort of individuals with at least one a¡ected sibling, and computes the in-
cidence rates in this cohort. The SIR were calculated only in families of
two or more siblings.
The PAF of cases with a family history of invasive melanoma was estimated
as follows: proportion of cases with a family history (familial SIR-1)/
familial SIR, as de¢ned by Miettinen (1974) and cited in a textbook as for-
mula 16^21 (Rothman and Greenland, 1998). In calculating PAF, we de¢ne
probands in three ways: only a¡ected parent or sibling, or a¡ected parent and
sibling.
RESULTS
The study was based on 24818 cases of invasive cutaneous mela-
noma and 5510 cases of in situ melanoma. The number of o¡-
spring (the o¡spring cohort from whom the expected number
of cases are calculated for the parent^o¡spring analysis) was 9771
in invasive melanoma and 2446 in in situ melanoma. The corre-
sponding numbers in the analysis of sibling risk were 8062 and
2027, as only families with at least two o¡spring were selected.
The incidence rates for invasive and in situ melanoma in Sweden
for the period 1961^98 (standardized according to European stan-
dard population) are shown in Fig 1. There has been an increase
for male and female rates throughout the period; in the case of in
situ melanoma particularly after 1985. The rates were equally high
between the genders in invasive melanoma, whereas in in situ
melanoma female rates were somewhat higher.
Familial risks in o¡spring In this section we show results on
melanoma risk in o¡spring when parents were diagnosed with
melanoma, irrespective of whether siblings were also a¡ected.
Familial risks for invasive melanoma were 2.41 and 3.15 when a
parent presented with one invasive or in situ disease, respectively
(Table I). The corresponding SIR for in situ melanoma were 4.03
and 2.92. We considered also familial risks in o¡spring by
multiple melanomas in parents. When a parent presented with
two invasive melanomas, the o¡spring SIRs were 8.02 and 11.71
for invasive and in situ melanoma, respectively. If the parent
additionally had an in situ melanoma, the SIRs were 23.18 and
61.78.When parental invasive melanoma risks were analyzed, the
same trend was observed; SIRs in parents were 1.91 (n¼ 219; 95%
CI: 1.67^2.19) and 17.50 (n¼ 4; 95% CI: 4.55^45.26) when
o¡spring had one invasive, or two invasive and one in situ
melanoma, respectively (data not shown).
Table II shows familial risks by histogenetic type; however,
these codes were only available from year 1993 and thus the
numbers of cases were decreased. SIRs in Table II were
calculated by considering only the person-years of life after 1993
in the o¡spring, whereas parental cancers were diagnosed at any
time. Among invasive types, super¢cially spreading melanoma
showed the highest risk of 2.61, compared with 2.15 (0.92^4.26)
for nodular melanoma. For in situ types, super¢cially spreading
melanoma showed a high risk of 5.40, whereas the SIR for
lentigo type was not signi¢cantly increased. w2 heterogeneity
test showed no signi¢cant di¡erences between subtypes of
invasive or in situ melanoma.
O¡spring melanoma was analyzed in terms of any invasive
cancer in parents (Table III). In addition to melanoma,
associations were noted between both forms of melanoma and
nervous system cancer. Invasive melanoma associated with breast
and skin (squamous cell) cancer. In situmelanoma associated with
thyroid and connective tissue cancers and multiple myeloma.
There was no evidence on the association of melanoma and
non-Hodgkin’s lymphoma in families. When the associations
were studied reversed way, as risk for cancer in o¡spring by
parental melanoma, skin and nervous system cancers remained
increased with SIR of 1.56 (n¼ 27; 95% CI: 1.03^2.20) and 1.25
(n¼105; 95% CI: 1.03^1.51), respectively.
E¡ects of age and proband status on invasive melanoma In
this section we cover only invasive melanoma by distinguishing
three mutually exclusive proband groups: only parent with
melanoma, only sibling with melanoma, and both parent and
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Figure1. Age-standardized incidence rate of invasive and in situ
melanoma in years 1961^98.
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Table I. SIR for melanoma in o¡spring by multiple parental melanoma
Invasive melanoma in o¡spring In situ melanoma in o¡spring
Parental melanoma history O SIR 95%CI O SIR 9s5%CI
1 invasive 214 2.41 2.10 2.76 88 4.03 3.23 4.96
1 in situ 53 3.15 2.36 4.12 12 2.92 1.50 5.12
1 invasive and 1 in situ 6 5.44 1.96 11.92 0
2 invasive 14 8.02 4.37 13.50 5 11.71 3.70 27.55
2 in situ 1 3.17 0.00 18.18 1 12.71 0.01 72.83
2 invasive and 1 in situ 3 23.18 4.37 68.63 2 61.78 5.82 227.19
1 invasive and 2 in situ 1 15.84 0.01 90.81 0
Invasive, any 241 2.63 2.30 2.98 96 4.24 3.44 5.18
In situ, any 64 3.44 2.65 4.40 15 3.31 1.84 5.46
O, Observed cases; CI, con¢dence interval.
Bold type: 95%CI does not include 1.00.
Table II. SIR for histopathological type of melanoma in o¡spring by any parental invasive melanoma
Invasive melanoma in o¡springb In situ melanoma in o¡springc
Type O SIR 95%CI Type 0 SIR 95%CI
Melanoma, non-speci¢ed 31 2.11 1.43 3.00 In situ , non-speci¢ed 25 3.64 2.36 5.39
Super¢cially spreading 49 2.61 1.93 3.45 Super¢cially spreading 8 5.40 2.30 10.68
Nodular 8 2.15 0.92 4.26 Lentigo 3 1.89 0.36 5.59
Other 2 1.75 0.17 6.44 Other 1 1.29 0.00 7.41
All melanoma 90 2.35 1.89 2.89 All melanoma 37 3.46 2.43 4.77
aPeriod of follow-up: 1993^1998. O, Observed cases; CI, con¢dence interval.
Bold type: 95%CI does not include 1.00.
bw2 test for heterogeneity¼ 4.6 on 3 d.f.; p¼ 0.2
cw2test for heterogeneity ¼ 6.2 on 3 d.f.; p¼ 0.1
Table III. SIR for melanoma in o¡spring by parental cancern
Melanoma in o¡spring In Situ Melanoma in o¡spring
Parental Invasive O SIR 95%CI O SIR 95%CI
Oral 102 1.01 0.80 1.24 19 0.66 0.35 1.06
Esophagus 30 1.03 0.68 1.45 10 1.34 0.61 2.35
Stomach 220 0.97 0.83 1.12 52 0.98 0.70 1.30
Colorectal adenocarcinoma 496 1.05 0.94 1.15 120 1.03 0.84 1.25
Liver 131 0.89 0.72 1.07 28 0.75 0.47 1.11
Pancreas 149 1.11 0.92 1.31 29 0.94 0.61 1.34
Lung 318 1.02 0.90 1.14 76 0.95 0.73 1.20
Breast 538 1.12 1.02 1.22 135 1.15 0.96 1.37
Cervix 74 0.78 0.60 0.98 17 0.84 0.51 1.26
Endometrium 110 1.01 0.82 1.22 26 0.95 0.60 1.37
Ovary 94 0.94 0.75 1.15 28 1.00 0.63 1.45
Other female genitals 14 0.92 0.50 1.46 5 0.50 0.05 1.42
Prostate 589 1.01 0.93 1.10 161 1.12 0.95 1.31
Kidney 144 1.01 0.84 1.18 44 1.18 0.84 1.58
Bladder 210 1.03 0.89 1.18 58 1.10 0.82 1.42
Melanoma 241 2.63 230 2.98 96 4.24 3.44 5.18
Skin 191 1.40 1.20 1.61 34 0.96 0.65 1.32
Nervous system 141 1.20 1.01 1.41 43 1.45 1.04 1.92
Thyroid 33 1.01 0.69 1.39 16 1.97 1.13 3.06
Endocrine 82 1.18 0.93 1.45 26 1.50 0.98 2.13
Connective tissue 30 1.16 0.78 1.61 13 2.00 1.06 3.24
Non-Hodgkin’s lymphoma 120 1.06 0.88 1.26 32 1.11 0.75 1.53
Multiple myeloma 66 1.03 0.79 1.29 25 1.58 1.02 2.27
Leukemia 124 1.08 0.90 1.28 35 1.23 0.86 1.67
Total 4247 1.07 1.03 1.10 1128 1.13 1.06 1.19
nCancer sites with less than 5 cases excluded.
O, Observed cases; CI, con¢dence interval.
Bold type: 95%CI does not include 1.00.
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sibling with melanoma.Table IV shows the age-speci¢c risks for
o¡spring invasive melanoma by age at diagnosis when only a
parent was a¡ected. The table was constructed for guidance to a
clinical counseling situation when an o¡spring of an a¡ected
parent is being advised. Because of di¡erent age truncations, the
o¡spring and parental diagnostic ages are not symmetrical. The
highest risk was at the youngest diagnostic age groups of
o¡spring, SIR 8.71 and 10.02, when a parent was diagnosed
before age 50 y.
Table V gives familial SIR for a¡ected siblings. Young
diagnostic age was a risk factor, showing the highest SIR of 5.85
for siblings, both of whom were diagnosed before age 30. No
clear age-dependent trend can be discerned at higher ages. We
do not show a separate table for the third proband group (both a
parent and a sibling a¡ected) because only 10 such triplets were
identi¢ed and some detailed data are shown below. The SIR for
this group was 8.92 (95% CI: 4.25^15.31).
PAF PAF depends on both the familial risk and the proportion
of familial cases among all o¡spring melanomas, and both of
these depend on age. InTable VI we show o¡spring SIR in age
groups and the related proportions, to enable calculation of PAF.
The total SIRs for the three proband groups were 2.40, 2.98, and
8.92. The comparable proportions were 2.36, 1.81, and 0.12%, thus
giving a PAF of 1.38, 1.20, and 0.10%. A combined PAF would
thus be 2.69%. The total PAF represents an average of the age-
speci¢c PAF factors. In Fig 2 age-speci¢c SIRs from Table VI
are plotted by parental or sibling family history. Figure 2 also
includes a graph for o¡spring when the parental age was limited
to 66 y, to make it comparable with age of the o¡spring
population. This truncation caused a small elevation in the SIR
curve. The SIR for o¡spring by 0^66 y old parent was 2.82
(n¼153; 95% CI: 2.39^2.28).
DISCUSSION
Familial risk may be due to heritable or environmental e¡ects, or
their interactions. For melanoma, skin type and pigmentation
could be a heritable cause and exposure to solar UV an environ-
mental cause; however, according to the previous Swedish
studies, shared environment only accounted for 10% of the
variance in melanoma risk between all types of family members,
compared with 21% for heritable and 69% random environmen-
tal e¡ects (Czene et al, 2002). Moreover, spouse concordance for
melanoma can only be observed for the early onset disease (Hem-
minki et al, 2001a; Hemminki and Jiang, 2002).These data suggest
that most familial clustering of melanoma is due to heritable
causes.
We have previously used an earlier version of the Swedish
Family Cancer Database to assess familial risks in invasive
melanoma, but no in situ cases were included and the analysis
Table IV. Age-speci¢c SIRs for melanoma by parental history of melanoma
Parental age at
O¡spring’s age at diagnosis
diagnosis 0^19 20^29 30^39 40^49 50^66
0^39 O 4 7 6 0 0
SIR 8.71 4.03 4.52
95% CI 2.27 19.34 1.60 7.58 1.63 8.86
40^49 O 7 11 12 3 3
SIR 10.02 3.22 3.13 1.15 4.09
95% CI 3.97 18.82 1.60 5.40 1.61 5.14 0.22 2.83 0.77 10.02
50^59 O 3 10 24 13 3
SIR 4.43 2.27 3.51 2.23 1.15
95% CI 0.83 10.85 1.08 3.89 2.25 5.06 1.18 3.60 0.22 2.82
60^69 O 1 9 16 23 16
SIR 2.07 2.38 1.86 2.40 3.34
95% CI 0.00 8.13 1.08 4.19 1.06 2.89 1.52 3.48 1.90 5.17
70þ O 0 4 15 21 20
SIR 1.58 1.98 1.68 1.93
95% CI 0.41 3.50 1.10 3.10 1.04 2.47 1.18 2.87
O, Observed cases; CI, con¢dence interval.
Bold type: 95% CI does not include 1.00.
TableV. Age-speci¢c SIRs for melanoma by sibling’s history of melanoma
Sibling’s age
Age at diagnosis
at diagnosis 15^29 30^39 40^49 50^66
15^29 O 8 3 5 0
SIR 5.85 1.61 3.11
95% CI 2.50 10.61 0.30 3.96 0.98 6.43
30^39 O 3 12 9 8
SIR 1.64 3.20 2.05 2.92
95% CI 0.31 4.01 1.65 5.27 0.93 3.60 1.25 5.30
40^49 O 5 10 34 15
SIR 2.97 2.21 4.88 2.76
95% CI 0.94 6.15 1.05 3.80 3.38 6.66 1.54 4.34
50^66 O 0 8 15 22
SIR 0.00 2.73 2.69 3.61
95% CI 1.11 1.11 1.17 4.96 1.50 4.22 2.26 5.27
O, Observed cases; CI, con¢dence interval.
Bold type: 95% CI does not include 1.00.
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did not cover histogenetic types, di¡erent proband groups or PAF
(Hemminki et al, 2001c). Melanoma has also been considered
among all main cancer sites from a previous version of the Data-
base, and the risk from a parental proband was given as 2.41, iden-
tical to the present estimate of 2.40, presently based on the 0^66 y
old o¡spring population (Dong and Hemminki, 2001a). A recent
summary estimate for familial melanoma risks between ¢rst-de-
gree relatives was 2.5 (95% CI: 2.1^3.0) (Peto and Houlston, 2001).
We show additionally here that when only a sibling was a¡ected,
the SIRwas 2.98; however, when the parental age was limited to
66 y, comparable with the age of o¡spring, the SIRwas 2.82, in-
dicating that the risks from parental and sibling probands were
practically identical. Histogenetic types of melanoma were only
available from years 1993 to 1998, and the number of familial cases
by any parental invasive melanoma was limited. Super¢cially
spreading melanoma, the most common type in Sweden (Man-
sson-Brahme et al, 2002), showed the highest risk of 2.61 among
invasive tumors; SIR for nodular melanoma was 2.15 and it did
not reach statistical signi¢cance. Super¢cially spreading melano-
ma showed also the highest risk, 5.40 for in situ melanomas. The
lentigo maligna in situ form was not signi¢cant with a SIR of
1.89. Super¢cially spreading and nodular melanomas are located
commonly on the trunk and they are related to intermittent sun
exposure (Elwood, 1992; Cox et al, 1996; Elwood and Gallagher,
1998; Gillgren et al, 1999). Lentigo maligna is common at
sun-exposed sites in old people.
Whereas the two mutually exclusive proband groups, parents
and siblings, could signal dominant and recessive e¡ects, respec-
tively, they could not distinguish low penetrant dominant e¡ects.
The equal magnitude of the SIR from parent and sibling may be
due to chance, or it may support the operation of low penetrant
dominant heritable mechanisms. The third proband group with
an a¡ected parent and o¡spring was likely to identify families
with high penetrant susceptibility genes, such as CDKN2A. The
high SIR of 8.92 (95% CI: 4.25^15.31) for o¡spring in these
families argue for the biologic basis for the clustering rather than
chance, which would be very unlikely. Also, multiple melanomas
in a patient, which showed high familial risks in this study, were
probably due to genetic susceptibility. Accordingly, CDKN2A
mutations have been reported from patients with multiple mela-
noma (Burden et al, 1999).The penetrance of CDKN2Amutations
was recently estimated at 76% for the analyzed US families by
age 80 y (Bishop et al, 2002). In an international comparison, pe-
netrance correlated with the background risk of melanoma.
PAF have been commonly calculated for environmental expo-
sures but for familial cancer limited data are available, and to the
best of our knowledge none speci¢cally on melanoma (Risch,
2001; Hemminki, 2002). Even the concept of PAF for family his-
tory is less concrete than that for an environmental exposure
(Hemminki and Czene, 2002). Genes are inherited from parents,
and thus the mechanistically interpreted PAF for heritable e¡ects
should only consider the parent^o¡spring relationship; however,
because of low penetrance, the parent^o¡spring relationship
would underestimate the magnitude of heritable e¡ects. Here we
give an example on a possible compensation for low-penetrant
e¡ects by adding PAF up from various probands, which can be
done if the proband categories are mutually exclusive, as in this
study. The derived PAF were 1.38% from a parent, 1.20% from a
sibling, and 0.10% from a parent and a sibling, summing up to
2.69% (Table VI). Based on analysis of all main sites of cancer,
these PAF values were intermediate (Hemminki and Czene,
2002). Even though the familial risk was relatively high for mel-
anoma, the proportion of o¡spring with an a¡ected family mem-
ber was relative small, in£ating the PAF. Indeed, 2.36% of the
a¡ected o¡spring had an a¡ected parent, which was far below
the cited ¢gures from Australia and the U.S.A., 6^14% (Gold-
stein andTucker, 1995; Ang et al, 1998). In a Utah cohort study like
ours, the proportion with an a¡ected ¢rst-degree relative was
3.9% (Goldgar et al, 1994). The reasons for the di¡erence could
be in the de¢nition or magnitude of familial predisposition, in
the environmental modi¢cation of the familial risk through ex-
posure to sun, or in technical bias introduced in case-control stu-
dies by an inaccurate reporting of malignancies in family
members.
To the best of our knowledge, no previous estimates are avail-
able on familial risks for in situ melanoma, except for our older
study on all in situ cancers (Hemminki andVaittinen, 1998a). That
study noted for many neoplasms that the in situ forms displayed a
higher familial risk than the invasive counterparts. The same ap-
peared to be true for in situmelanoma in our study. InTable I, the
highest familial risk was for in situmelanoma by parental invasive
melanoma, thus indicating that in families both invasive and in
situ cases occurred, as they did occur in single individuals as mul-
tiple tumors (Table II). Thus there was no evidence that the two
forms were separate entities; however, whether the in situ form is
a precursor lesion to invasive melanoma does not appear to be
settled (see Wassberg et al, 1999b). One reason for the apparently
higher familial risks for in situ tumors is that they may be re-
moved in suspicion of malignancy preferentially in a¡ected fa-
milies. Although the high level of histologic con¢rmation of
malignancy in cases reported to the Swedish Cancer Registry
would guard against false diagnosis, increasing vigilance would
result in earlier diagnosis, which would cause a lead-time bias,
and an apparent increase in familial risk.
Socio-economic status may be an intervening factor in the
analysis of familial associations across cancer sites. For this reason
we adjusted the data for socio-economic status. A limited num-
ber of cancers associated with melanoma in families (Table III).
As one, the aggregation of melanoma and squamous cell carcino-
ma of the skin was evident but the risk was only to invasive mel-
anoma. Skin was also the only discordant cancer site that
associated with sibling risk for invasive melanoma with a SIR of
1.97 (n¼ 24; 95% CI: 1.26^2.83; data not shown).The aggregation
may be due to a shared risk factor, or a shared sensitivity to UV
radiation (English et al, 1997). These associations have been noted
in the second skin cancer after the ¢rst melanoma (Swerdlow
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Figure 2. SIR of invasive melanoma in o¡spring as a function of
diagnostic age according to parental or sibling probands. An addi-
tional graph shows the SIR for o¡spring whose parents were limited to
age 66 y. Note that numbers of cases, SIR and 95% CI for the o¡spring
and sibling data are shown inTableVI.
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et al, 1995;Wassberg et al, 1996, 1999a; Schenk et al, 1998) and in the
second melanoma after the ¢rst skin cancer (Frisch and Melbye,
1995; Levi et al, 1997, 1998; Wassberg et al, 1999b; Hemminki and
Dong, 2000a, b). Invasive melanoma also associated with breast
and nervous system cancers, associations of which have been re-
cognized previously (Hemminki et al, 2001c). The melanoma-
breast cancer association is linked to germline CDKN2A (Borg
et al, 2000; Plna and Hemminki, 2001) and BRCA2 mutations
(The Breast Cancer Linkage Consortium, 1999). The association
to nervous system tumors is mainly due to brain astrocytomas
(Hemminki et al, 2001b).The association of in situmelanoma with
thyroid cancer may be a chance ¢nding because no excess was
observed for invasive melanoma. The same was true for connec-
tive tissue neoplasms, but these have been associated earlier with
invasive melanoma when parental melanoma risks were analyzed
(Hemminki et al, 2001c). A study on soft tissue tumors found no
association to melanoma (Hemminki and Li, 2001). No associa-
tion was noted for familial melanoma and non-Hodgkin’s lym-
phoma. In an earlier study from this Database a marginal
clustering was observed (Hemminki et al, 2001c), and there are
some contradictory results on an increased risk of subsequent
melanoma after an initial non-Hodgkin’s lymphoma (Travis et al,
1991, 1993; Adami et al, 1995; Levi et al, 1996; Brennan et al, 2000;
Dong and Hemminki, 2001b).
In summary, this large study on familial melanoma showed an
equal risk from parents and siblings, clear age dependence in risk,
and somewhat higher risk in in situ melanoma than in the inva-
sive counterpart. The highest risk was in families were two o¡-
spring and a parent were a¡ected, and in those families where a
proband had multiple melanomas. Melanoma associated with
breast, nervous system, and skin cancers, and in situ melanoma
possibly also with connective tissue and thyroid tumors.
The Family Cancer Database was created by linking registers maintained at Statistics
Sweden and the Swedish Cancer Registry. The study was supported by David &
Astrid Hagelen’s Foundation and the Swedish Cancer Society and King Gustaf V’s
Jubilee Fund.
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